Johannes Ettl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9457682/publications.pdf

Version: 2024-02-01

67 papers	3,039 citations	304743 22 h-index	161849 54 g-index
88 all docs	88 docs citations	88 times ranked	4438 citing authors

#	Article	IF	Citations
1	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncology, The, 2015, 16, 25-35.	10.7	1,574
2	First Experience with Chemokine Receptor CXCR4â€“Targeted PET Imaging of Patients with Solid Cancers. Journal of Nuclear Medicine, 2016, 57, 741-746.	5.0	109
3	PROutine: a feasibility study assessing surveillance of electronic patient reported outcomes and adherence via smartphone app in advanced cancer. Annals of Palliative Medicine, 2019, 8, 104-111.	1.2	75
4	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2â˜’ advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Research and Treatment, 2020, 183, 419-428.	2.5	73
5	Polyurethane versus silicone catheters for central venous port devices implanted at the forearm. European Journal of Cancer, 2016, 59, 113-124.	2.8	62
6	Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist, 2020, 25, e439-e450.	3.7	61
7	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast, 2018, 37, 154-160.	2.2	56
8	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors â€“ Data from the German PRAEGNANT breast cancer registry. Breast, 2018, 37, 42-51.	2.2	54
9	Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2â˜’ Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist, 2019, 24, 1514-1525.	3.7	49
10	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers, 2019, 11, 10.	3.7	43
11	Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. Archives of Gynecology and Obstetrics, 2017, 295, 1239-1245.	1.7	42
12	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Research and Treatment, 2019, 173, 319-328.	2.5	40
13	Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer â€”Association With Patient and Disease Characteristics and Effect on Prognosis. Journal of Clinical Oncology, 2021, 39, 1619-1630.	1.6	39
14	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. European Journal of Cancer, 2021, 155, 1-12.	2.8	39
15	Mechanic and surface properties of central-venous port catheters after removal: A comparison of polyurethane and silicon rubber materials. Journal of the Mechanical Behavior of Biomedical Materials, 2016, 64, 281-291.	3.1	38
16	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer â€” Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast, 2020, 54, 88-95.	2.2	34
17	Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-Cancer Drugs, 2018, 29, 271-280.	1.4	33
18	PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma. EJNMMI Research, 2018, 8, 90.	2.5	31

#	Article	IF	Citations
19	Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors. Breast Care, 2019, 14, 86-92.	1.4	28
20	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. Breast Cancer Research and Treatment, 2016, 158, 59-65.	2.5	27
21	The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial. Clinical Breast Cancer, 2017, 17, 100-106.	2.4	27
22	Update Breast Cancer 2019 Part 3 â€“ Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2019, 79, 470-482.	1.8	26
23	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. Geburtshilfe Und Frauenheilkunde, 2017, 77, 870-878.	1.8	24
24	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptorâ€“positive/human epidermal growth factor receptor 2â€“negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Research, 2020, 22, 27.	5.0	24
25	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physicianâ€™s Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectrum, 2020, 4, pkz085.	2.9	24
26	Update Breast Cancer 2018 (Part 2) â€“ Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Und Frauenheilkunde, 2018, 78, 246-259.	1.8	23
27	Update Breast Cancer 2019 Part 2 â€“ Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Und Frauenheilkunde, 2019, 79, 268-280.	1.8	21
28	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Research and Treatment, 2020, 184, 23-35.	2.5	21
29	Update Breast Cancer 2018 (Part 1) â€“ Primary Breast Cancer and Biomarkers. Geburtshilfe Und Frauenheilkunde, 2018, 78, 237-245.	1.8	20
30	Update Breast Cancer 2017 â€“ Implementation of Novel Therapies. Geburtshilfe Und Frauenheilkunde, 2017, 77, 1281-1290.	1.8	19
31	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. Cancers, 2020, 12, 3317.	3.7	19
32	The Predictive Value ofPITX2DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. Disease Markers, 2017, 2017, 1-14.	1.3	18
33	Update Breast Cancer 2019 Part 4 â€“ Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1079-1089.	1.8	18
34	Update Breast Cancer 2019 Part 1 â€“ Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 256-267.	1.8	17
35	Update Breast Cancer 2019 Part 5 â€“ Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1090-1099.	1.8	16
36	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. Current Opinion in Obstetrics and Gynecology, 2019, 31, 67-75.	2.0	16

#	Article	IF	Citations
37	Update Breast Cancer 2020 Part 1 â€“ Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Und Frauenheilkunde, 2020, 80, 277-287.	1.8	16
38	Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1. PLoS ONE, 2017, 12, e0183917.	2.5	15
39	Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results. Breast, 2020, 49, 101-107.	2.2	13
40	Update Breast Cancer 2020 Part 3 â€“ Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1105-1114.	1.8	12
41	Update Breast Cancer 2020 Part 2 â€“ Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Und Frauenheilkunde, 2020, 80, 391-398.	1.8	12
42	Translational Highlights in Breast and Ovarian Cancer 2019 â€“ Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1309-1319.	1.8	11
43	Update Breast Cancer 2020 Part 4 â€“ Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1115-1122.	1.8	11
44	Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer. Breast Care, 2016, 11, 174-176.	1.4	10
45	The safety and efficacy of palbociclib in the treatment of metastatic breast cancer. Expert Review of Anticancer Therapy, 2017, 17, 661-668.	2.4	9
46	ABC3 Consensus: Assessment by a German Group of Experts. Breast Care, 2016, 11, 61-70.	1.4	8
47	Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial. Breast Cancer, 2017, 24, 319-325.	2.9	8
48	Update Breast Cancer 2018 (Part 3) â€“ Genomics, Individualized Medicine and Immune Therapies â€“ in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1110-1118.	1.8	8
49	ABC4 Consensus: Assessment by a German Group of Experts. Breast Care, 2018, 13, 48-58.	1.4	7
50	MRI based neuroanatomical segmentation in breast cancer patients: leptomeningeal carcinomatosis vs. oligometastatic brain disease vs. multimetastastic brain disease. Radiation Oncology, 2019, 14, 170.	2.7	6
51	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers, 2020, 12, 3021.	3.7	6
52	First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer. Archives of Gynecology and Obstetrics, 2020, 302, 1461-1467.	1.7	6
53	Characterization of long-term responders following treatment with talazoparib (TALA) or physicianâ€™s choice of chemotherapy (PCT) in the phase 3 embraca trial.. Journal of Clinical Oncology, 2021, 39, 1029-1029.	1.6	5
54	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1134-1142.	1.8	4

#	Article	IF	Citations
55	Update Breast Cancer 2018 (Part 4) â€“ Genomics, Individualized Medicine and Immune Therapies â€“ in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1119-1128.	1.8	3
56	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients â€“ a Survey Among Physicians. Geburtshilfe Und Frauenheilkunde, 2018, 78, 707-714.	1.8	3
57	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. Breast Care, 2021, 16, 108-114.	1.4	3
58	Molecular Tumor Boards. Breast Care, 2018, 13, 137-139.	1.4	2
59	Luminal Metastatic Breast Cancer: Current Concepts and Future Approaches. Breast Care, 2021, 16, 99-100.	1.4	2
60	Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study.. Journal of Clinical Oncology, 2012, 30, 556-556.	1.6	2
61	Iyengar yoga compared to exercise in women with stage I-III breast cancer: Feasibility of therapeutic interventions during adjuvant cytotoxic or endocrine therapy.. Journal of Clinical Oncology, 2013, 31, e20623-e20623.	1.6	2
62	Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer, 2020, 20, 1091.	2.6	1
63	Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).. Journal of Clinical Oncology, 2020, 38, 1018-1018.	1.6	1
64	Nipple-sparing subcutaneous mastectomy (NSSM) as dual-plane prosthetic reconstruction using the modified Wise pattern mastectomy, fasciocutaneous flap, and titan-polypropylen-mesh-interponation in women with macromastia.. Journal of Clinical Oncology, 2012, 30, 156-156.	1.6	0
65	Risk factors for the incidence of breast cancer after prophylactic mastectomy.. Journal of Clinical Oncology, 2015, 33, e12545-e12545.	1.6	0
66	CLO20-052: Hospitalization and Supportive Care Medication (SCM) Utilization Among Patients Treated With Talazoparib (TALA) Monotherapy: An Integrated Analysis of Five Clinical Trials (Phase 1-3) in Advanced Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, CLO20-052.	4.9	0
67	Abstract P5-13-08: Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study. Cancer Research, 2022, 82, P5-13-08-P5-13-08.	0.9	0